Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters

Molecular Cancer Therapeutics

Volumn 6, Issue 12, 2007, Pages 3229-3238

  Takagi, Kazutaka ^a   Dexheimer, Thomas S ^a   Redon, Christophe ^a   Sordet, Olivier ^a   Agama, Keli ^a   Lavielle, Gilbert ^b   Pierré, Alain ^b   Bates, Susan E ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; HISTONE H2AX; LACTONE; MULTIDRUG RESISTANCE PROTEIN 1; OXYGEN; S 38809; S 39625; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DRUG ACTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; PRIORITY JOURNAL; PROSTATE CANCER; RING OPENING; STRUCTURE ACTIVITY RELATION; YEAST;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BASE SEQUENCE; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CELL LINE, TUMOR; DNA; DNA PRIMERS; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HUMANS; HYDROLYSIS; MOLECULAR STRUCTURE;

EID: 37549071516     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0441     Document Type: Article

References (49)

1. Wall ME, Wani MC, Cooke CE, Palmer KH, McPhail AT, Slim GA. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966;88:3888-90.
2. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
3. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-6.
4. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 1989;49:1465-9.
5. Porter SE, Champoux JJ. The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res 1989;17:8521-32.
6. Staker BL, Feese MD, Cushman M, et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 2005;48:2336-45.
7. Jaxel C, Capranico G, Kerrigan D, Kohn KW, Pommier Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 1991;266:20418-23.
8. Eng WK, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 1988;34:755-60.
9. Nitiss J, Wang JC. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci U S A 1988;85:7501-5.
10. Bjornsti M-A, Benedetti P, Viglianti GA, Wang JC. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 1989;49:6318-23.
11. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A 2002;99:15387-92.
12. Marchand C, Antony S, Kohn KW, et al. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of topoisomerase I-DNA covalent complexes. Mol Cancer Ther 2006;5:287-95.
13. Pommier Y, Pourquier P, Urasaki Y, Wu J, Laco G. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 1999;2:307-18.
14. Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: current perspectives. Bioorg Med Chem 2004;12:1585-604.
15. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serumalbumin: impact on drug stability. J Med Chem 1994;37:40-6.
16. Lavergne O, Lesueur-Ginot L, Pla Rodas F, et al. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J Med Chem 1998;41:5410-9.
17. Bailly C. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit Rev Oncol Hematol 2003;45:91-108.
18. Urasaki Y, Takebayashi Y, Pommier Y. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations. Cancer Res 2000;60:6577-80.
19. Bates SE, Medina-Perez WY, Kohlhagen G, et al. ABCG2 mediates differential resistance to SN-38 and homocamptothecins. J Pharmacol Exp Ther 2004;310:836-42.
20. Hautefaye P, Cimetiere B, Pierre A, et al. Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin. Bioorg Med Chem Lett 2003;13:2731-5.
21. Lansiaux A, Leonce S, Kraus-Berthier L, et al. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs. Mol Pharmacol 2007;72:311-9.
22. Hoki Y, Fujimori A, Pommier Y. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother Pharmacol 1997;40:433-8.
23. Brangi M, Litman T, Ciotti M, et al. Camptothecin resistance: role of the ATP binding cassette (ABC) half-transporter, mitoxantrone-resistance (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999;59:5938-46.
24. Antony S, Jayaraman M, Laco G, et al. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Res 2003;63:7428-35.
25. Miao ZH, Player A, Shankavaram U, et al. Non-classical functions of human topoisomerase I: genome-wide and pharmacological analyses. Cancer Res 2007;67:8752-61.
26. Urasaki Y, Laco G, Pourquier P, et al. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res 2001;61:1964-9.
27. Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell resistant to camptothecin. Cancer Res 1995;55:1339-46.
28. Pommier Y, Laco GS, Kohlhagen G, Sayer JM, Kroth H, Jerina DM. Position-specific trapping of topoisomerase I-DNA cleavage complexes by intercalated benzo[a]-pyrene diol epoxide adducts at the 6-amino group of adenine. Proc Natl Acad Sci U S A 2000;97:10739-44.
29. Pourquier P, Pilon A, Kohlhagen G, Mazumder A, Sharma A, Pommier Y. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps: importance of DNA end phosphorylation and camptothecin effects. J Biol Chem 1997;272:26441-7.
30. Strumberg D, Pommier Y, Paull K, Jayaraman M, Nagafuji P, Cushman M. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. J Med Chem 1999;42:446-57.
31. Nitiss JL, Liu Y-X, Hsiung Y. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res 1993;53:89-93.
32. Byl JA, Fortune JM, Burden DA, et al. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement. Biochemistry 1999;38:15573-9.
33. Shaw JL, Blanco J, Mueller GC. A simple procedure for isolation of DNA, RNA and protein fractions from cultured animal cells. Anal Biochem 1975;65:125-31.
34. Subramanian D, Kraut E, Staubus A, Young DC, Mutter MT. Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res 1995;55:2007-103.
35. Pourquier P, Takebayashi Y, Urasaki Y, Gioffre C, Kohlhagen G, Pommier Y. Induction of topoisomerase I cleavage complexes by 1-β-D- arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci U S A 2000;97:1885-90.
36. Kohn KW. DNA filter elution: a window on DNA damage in mammalian cells. Bioessays 1996;18:505-13.
37. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
38. Robey RW, Honjo Y, Morisaki K, et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 2003;89:1971-8.
39. Furuta T, Takemura H, Liao ZY, et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA-double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 2003;278:20303-12.
40. Covey JM, Jaxel C, Kohn KW, Pommier Y. Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 1989;49:5016-22.
41. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994;86:836-42.
42. Tanizawa A, Kohn KW, Kohlhagen G, Leteurtre F, Pommier Y. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 1995;34:7200-6.
43. Rajendra R, Gounder MK, Saleem A, et al. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res 2003;63:3228-33.
44. Redon C, Pilch D, Rogakou E, Sedelnikova O, Newrock K, Bonner W. Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev 2002;12:162-9.
45. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
46. Pommier Y, Cherfils J. Interfacial protein inhibition: a nature's paradigm for drug discovery. Trends Pharmacol Sci 2005;28:136-45.
47. Pommier Y, Marchand C. Interfacial inhibitors of protein-nucleic acid interactions. Curr Med Chem Anti-Canc Agents 2005;5:421-9.
48. Huang X, Traganos F, Darzynkiewicz Z. DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis. Cell Cycle 2003;2:614-9.
49. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 2000;275:9390-5.